Merck's Keytruda blazes a path in first-line cervical cancer, making good on drugmaker's push for earlier patients
In the years since I/O wonder drug Keytruda’s initial approval, Merck has struck an aggressive clinical trial program, which is now firmly focused on earlier lines of therapy. The drugmaker has scored some success there so far, and now it’s earned one of its biggest wins yet.
Keytruda plus chemotherapy with or without background Avastin significantly extended patients’ lives over those dosed with a placebo control in first-line patients with persistent, recurrent or metastatic cervical cancer, according to top-line data from the Phase III KEYNOTE-826 study revealed Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,300+ biopharma pros reading Endpoints daily — and it's free.